SELLAS Life Sciences Group, Inc. (SLS)
| Market Cap | 1.45B +848.4% |
| Revenue (ttm) | n/a |
| Net Income | -29.46M |
| EPS | -0.23 |
| Shares Out | 186.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,700,301 |
| Open | 7.67 |
| Previous Close | 7.56 |
| Day's Range | 7.35 - 8.27 |
| 52-Week Range | 1.39 - 9.10 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 10.00 (+28.54%) |
| Earnings Date | May 12, 2026 |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price target is $10.0, which is an increase of 28.54% from the latest price.
News
SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Late-stage oncology company advancing GPS (phase III, AML maintenance) and SLS-009 (phase II, frontline AML), both showing strong efficacy and safety signals. Key data readouts for both assets are expected by year-end, supported by a robust $110M cash position.
SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing two late-stage oncology assets, GPS and SLS009, both targeting AML with promising survival and response data. Imminent catalysts include phase III REGAL trial results for GPS and phase II data for SLS009, supported by strong biomarker strategies and financial resources.
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nov...
Sellas Life Sciences options imply 4.6% move in share price post-earnings
Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 16:1. Implied volatility suggests the market is anticipating a move near 4.6%, or 24c, after results…
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11...
SELLAS Life Sciences Group Quarterly report: Q1 2026
SELLAS Life Sciences Group has published its Q1 2026 quarterly earnings report on May 12, 2026.
SELLAS Life Sciences Group Earnings release: Q1 2026
SELLAS Life Sciences Group released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Sellas Life Sciences call volume above normal and directionally bullish
Bullish option flow detected in Sellas Life Sciences (SLS) with 7,282 calls trading, 1.8x expected, and implied vol increasing over 7 points to 130.21%. 5/1 weekly 6 calls and 5/1…
SELLAS Life Sciences Group Proxy statement: Proxy filing
SELLAS Life Sciences Group filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
SELLAS Life Sciences Group Proxy statement: Proxy filing
SELLAS Life Sciences Group filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
These 16 stocks are a short seller's dream — likely losers no matter what the market does
Borrowing costs eat into trading profits. These stocks are less expensive to short.
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: DeFi Development Corp (DFDV) 30.28% +4.39, SoundHound AI (SOUN) 10.74% +3.17, Sellas Life Sciences (SL...
Sellas Life Sciences files automatic mixed securities shelf
17:02 EDT Sellas Life Sciences (SLS) files automatic mixed securities shelf
Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global
Alliance Global raised the firm’s price target on Sellas Life Sciences (SLS) to $10 from $7.50 and keeps a Buy rating on the shares after the company presented updates on…
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
SELLAS Life Sciences Group Earnings release: Q4 2025
SELLAS Life Sciences Group released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
SELLAS Life Sciences Group Annual report: Q4 2025
SELLAS Life Sciences Group has published its Q4 2025 annual report on March 19, 2026.
Sellas Life Sciences options imply 6.2% move in share price post-earnings
Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 17:2. Implied volatility suggests the market is anticipating a move near 6.2%, or 30c, after results…
Sellas Life Sciences to present preclinical SLS009 data at AACR conference
Sellas Life Sciences (SLS) announced that preclinical data on SLS009, a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research, or…
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - - Preclinical data show that SLS009 lowers the apoptotic threshold in AML ce...
Sellas announces enrollment of first patient in Phase 2 SLS009 trial
SELLAS Life Sciences (SLS) Group announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009, a highly selective CDK9 inhibitor in newly diagnosed, first-line acute...
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Util...
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Sellas Life Sciences (SLS) 20.00% +1.62, MSOX ETF (MSOX) 14.83% +0.65, Humacyte (HUMA) 20.83% +0.62, V...
Mixed options sentiment in Sellas Life Sciences with shares down 1.75%
Mixed options sentiment in Sellas Life Sciences (SLS), with shares down 8c near $4.50. Options volume relatively light with 13k contracts traded and calls leading puts for a put/call ratio…
Sellas Life Sciences enters agreement with IMPACT-AML
SELLAS Life Sciences (SLS) announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advancing innovative treatments for patients with acute mye...